Transfusion guided by quality of life for MDS or AML
Part of Blood & lymphatic, Cancer clinical trials.
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have MDS or AML that is not being treated with a goal of cure (you are on palliative care)
- You have anemia (low red blood cells) with hemoglobin levels 8 g/dL or lower (or 9 g/dL if you have heart disease)
- You need more than 2 red blood cell transfusions every 8 weeks
- You do not have a vitamin or iron deficiency that would cause anemia
- You don't have an active uncontrolled infection, severe heart disease, or another cancer (except for some skin or cervical and breast cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This trial tests whether giving more or fewer red blood cell transfusions is better for adult patients on ECMO (a machine that helps your heart and lungs work). The goal is to find the best transfusion approach to improve outcomes.
This study tests whether giving blood transfusions based on each patient's needs during and after heart surgery is safe and effective. It compares different transfusion thresholds to see which works better.
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.